( NASDAQ-SMALL:ONCS )

News from OncoSec Medical Incorporated A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Sep 07, 2017, 06:00 ET OncoSec Appoints Industry Leader Daniel J. O'Connor to its Board of Directors

OncoSec Medical Incorporated "OncoSec" (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the...


Sep 06, 2017, 14:44 ET OncoSec Announces Presentations at Upcoming Investment and Scientific Conferences

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


Sep 05, 2017, 06:00 ET OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors

OncoSec Medical Incorporated ("OncoSec" or the "Company" (NASDAQ: ONCS)), a company developing DNA-based intratumoral cancer immunotherapies, today...


Jun 12, 2017, 06:01 ET OncoSec Announces Technology Access Program Agreement with Jounce Therapeutics, Inc.

OncoSec Medical Incorporated ("OncoSec") (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that...


Jun 08, 2017, 16:30 ET OncoSec Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Unresectable Metastatic Melanoma

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that...


Jun 02, 2017, 06:01 ET OncoSec to Present at LD Micro Invitational

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will be featured as a...


Jun 01, 2017, 16:01 ET OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2017

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced third...


May 11, 2017, 06:45 ET OncoSec to Host Third Quarter Financial Conference Call on June 1, 2017

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


May 10, 2017, 06:00 ET OncoSec Announces Clinical Collaboration with Merck to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Metastatic Melanoma

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has entered a clinical...


May 02, 2017, 08:43 ET OncoSec to Present at Biomarkers & Immuno-Oncology World Congress 2017

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


Apr 03, 2017, 08:01 ET OncoSec Presents Preclinical Data Demonstrating Improved Systemic Anti-Tumor Response Following Modifications to IL-12 Gene Delivery Therapy at AACR Annual Meeting

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented a...


Mar 28, 2017, 06:01 ET OncoSec to Present Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2017

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present...


Mar 21, 2017, 14:01 ET OncoSec Medical's Intratumoral Plasmid IL-12 Demonstrates Effectiveness at Enhancing Tumor Immunogenicity in Preclinical Tumor Models

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented a...


Mar 16, 2017, 16:01 ET OncoSec Announces Second Quarter and YTD Results for Fiscal Year 2017

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced...


Mar 14, 2017, 06:01 ET OncoSec Announces First Technology Access Program Agreement with Inhibrx

SAN DIEGO, March 14, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral...


Mar 07, 2017, 09:22 ET OncoSec to Present at Scientific and Investment Conferences in March

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present...


Mar 02, 2017, 06:01 ET OncoSec to Host Second Quarter Financial Conference Call on March 16, 2017

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


Feb 27, 2017, 06:01 ET OncoSec Granted FDA Fast Track Designation for ImmunoPulse® IL-12 for the Treatment of Metastatic Melanoma Following Progression on Pembrolizumab or Nivolumab

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, received Fast Track...


Feb 24, 2017, 06:01 ET OncoSec to Host KOL Event Focused on New ASCO-SITC Melanoma Data and Clinical Strategy on Tuesday, February 28 in New York City

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will host a Key...


Feb 23, 2017, 11:30 ET OncoSec Announces Positive Phase II Data Demonstrating Company's ImmunoPulse® IL-12 in Combination with Pembrolizumab Increased Response Rates in Anti-PD-1 Non-Responder Melanoma Patients

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today reported new...


Feb 08, 2017, 06:01 ET OncoSec to Present New Clinical Data from Phase 2 Combination Study at ASCO-SITC Clinical Immuno-Oncology Symposium and Corporate Updates at Two Investment Conferences in February

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present new...


Jan 26, 2017, 06:01 ET OncoSec to Present at NobleCon13

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that...


Jan 03, 2017, 06:01 ET OncoSec to Present at Investment Conferences in January

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


Dec 08, 2016, 16:01 ET OncoSec Announces First Quarter Financial Results for Fiscal Year 2017

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced...


Dec 01, 2016, 06:01 ET OncoSec to Present at the 9th Annual LD Micro Main Event

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...